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Abstract
The increased incidence of infections caused by methicillin-resistant
strains of Staphylococcus aureus (MRSA) burdens the healthcare sys-
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tems with significant additional costs. Simple measures such as active
MRSA screening can lead to a reduction of infectious events and
massive savings. To establish an effective and comprehensive strategy 1 RIEMSER Arzneimittel AG,
Medical Science & forpreventionanderadicationofMRSA,thecooperationandnetworking
Operations, Greifswald –
Insel Riems, Germany
ofallstakeholdersinthehealthcaresystemisnecessary.Pharmaceut-
ical companies are part of the health care system; they therefore have
a vital and ethical interest that care within the health system will be
further optimized and thus continue to remain affordable. The targets
oftheHIC@REprojectdemonstratetheinterestsofthepharmaceutical
and health-care research company RIEMSER Arzneimittel AG, so that
a sufficient rationale is given for cooperation in this project.
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Zusammenfassung
DasgehäufteAuftretenvonInfektionen,diedurchMethicillin-resistente
StämmevonStaphylococcusaureus(MRSA)verursachtwerden,belastet
die Gesundheitssysteme mit erheblichen Zusatzkosten. Einfache Maß-
nahmenwiedasaktiveMRSA-ScreeningkönnenbereitszueinerReduk-
tion der Infektionsereignisse und damit zu massiven Einsparungen
führen.ZurEtablierungeinereffektivenundflächendeckendenPräven-
tions-undEradikations-StrategieistjedochdieKooperationundVernet-
zung aller Akteure in der Gesundheitsversorgung erforderlich. Pharma-
zeutische Unternehmen haben ein vitales und ethisches Interesse
daran, dass die Versorgung im Gesundheitssystem weiterhin optimiert
wird und damit auch bezahlbar bleibt, weil sie Bestandteil dieses Sys-
tems sind. In den Zielen des HIC@RE-Projektes werden die Interessen
des in der Versorgungsforschung aktiven Pharmaunternehmens RIEM-
SER Arzneimittel AG abgebildet, so dass die Rationale für eine Projekt-
kooperation gegeben ist.
Schlüsselwörter:Multiresistenz,MRSA,S.aureus,Prävention,Screening,
Kosten, wirtschaftlicher Schaden
Introduction
Infections by multi-resistant bacteria (MRB) are a grow-
ing problem. This applies especially to infections caused
by methicillin-resistant Staphylococcus aureus (MRSA)
strains.
In the past, the prevalence of MRSA in Germany has also
increased dramatically. In the year 1990 the frequency
of MRSA in all bacterial isolates of S. aureus was just
1.7%, but rose to 15% in 1998 and to around 21% in
2001, respectively [1]. MRSA surveillance-data of recent
years reported a near doubling of MRSA cases for every
1,000 patient days from 0.63 in 2004 to 1.14 in 2009
[2].
According to the data from the European Antimicrobial
Resistance Surveillance System (EARSS) for 2006, the
incidence of MRSA bacteremia had risen to 25–50% of
all S. aureus-bacteremia in most southern European
countriesaswellasinFrance,BelgiumandGreatBritain.
In Germany at that time, the frequency of MRSA
bacteremia was between 10 and 25% of all bacteremia
with by S. aureus [3]. Local studies have shown that the
total rate of new nosocomial infections with S. aureus
correlates with the increase of MRSA-infections [4] indi-
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strains of S. aureus (MSSA) in an otherwise unchanged
overallincidence[5].Itisestimatedthataround150,000
patients in European health care facilities are infected
withMRSAeveryyearandthatabout44%ofallinfections
in health care facilities of the EU member states are
caused by MRSA [5].
Due to the massive increase of MRSA in hospitals and in
the population as well as the simultaneously escalating
pressure for rationalization in the health care system,
interest in the economic context has continuously in-
creasedduetothegrowingevidencethatamanagement
based on networking is necessary for the prevention and
control of MRB not only from the medical and ethical
point of view, but also already in mid-term of individual-
and macro-economic sense [6].
Cost factor MRSA
It has been reported in the available literature that the
costs of MRSA-infections are 1.2 to 2.8 times higher
than the costs of infections caused by methicillin-sensi-
tive strains of S. aureus [7], [8], [9], [10], [11]. MRSA-
infections can be of a localized or, of a severe and sys-
temic nature, like the MRSA-sepsis. The cost of noso-
comial MRSA-infections depends on their respective
clinical manifestation. Wernitz et al. [12] have calculated
that the cost of MRSA-pneumonia with around € 29,000
is particularly high whereas much lower cost are gener-
ated by MRSA-septicemia (appr. € 13,500), SSI (appr.
€ 11,300) and urinary tract infections (appr. € 4,500).
ApartfromthetreatmentoftheMRSA-infection,themain
costdrivingfactorsaretheprolongedhospitalizationand
necessary isolation of the patient, additional diagnostic
and hygiene measures as well as necessity to deploy
more staff for these patients.
In this context it is of interest to look at the results of a
Canadian study on 20 MRSA-patients in which the aver-
age additional cost per patient amounted to $ 14,360.
The average prolongation of hospitalization was 14 d for
thesepatients.Prolongedhospitalizationwasresponsible
for95%of the additionalcosts,whereas therapeutic and
diagnostic measures accounted only for 1% and 4% of
the additional costs, respectively [13].
According to an analysis of relevant studies, MRSA-
infections can cause average costs of $ 35,367. This
brings MRSA-infections to second place in the ranking of
costs generated by nosocomial infections behind sepsis
($ 38,703) but well ahead of pneumonia ($ 17,677) and
SSI ($ 15,646) [14].
Aretrospectivecase-controlstudyperformedonaninten-
sive care unit in France compared the costs between
27 patients with and 27 patients without MRSA. As a
result, average stay was 18 d for patients with MRSA and
14 d for patients without MRSA (p=0.02). Average costs
for an MRSA-patient were $ 30,225 and thus about one
third higher than the average costs for a control-patient
which were reported to $ 20,959 (p=0.004) [15].
The financial burden of MRSA
TheadditionalannualcostofnosocomialMRSA-infections
for the health care system of the EU countries is esti-
mated to be around € 380m [5]. The total financial bur-
den for the German economy has been calculated from
Wernitz and Veit [1] to be about € 146m. The health in-
suranceDAKcalculatedevenaminimumfinancialburden
of € 610,277,836 [16].
This burden is considerable especially when taking into
account that consequential costs associated with re-
habilitation, insurance claims and additional cost items
that may arise as a result of long term morbidity are not
included. In this context it has been shown that, depend-
ing on the clinical manifestation, MRSA-infections may
causefinanciallossesforthetreatinghealthcarefacilities
ofupto€22,000perpatientunderDRG-conditions[12].
This data demonstrates that efficient strategies for the
prevention of MRSA-infections are absolutely essential.
Cost reduction by active screening
Surveillance data from 199 German hospitals for 2009
showedthat72.52%of28,195MRSA-caseswerebrought
into the hospital by the patients themselves [2]. In add-
ition it is assumed that a pre-existing colonization with
MRSA is an independent predictive factor for the devel-
opment of an MRSA-infection [17], [18]. However, a high
percentageofMRSA-carrierscanbediscoveredbyactive
screening [19]. It has been shown that the intranasal
application of Mupirocin leads to a significant reduction
of nosocomial S. aureus infections of nasal carriers
(p=0.02)[20].Correspondingly,publisheddatashowthat
active screening and decontamination of colonized pa-
tients can lead to significant savings. Thus, the cost in-
curred for the initial screening of 539 patients (=1.5% of
alladmittedpatientswithin19months)hasbeenreported
to be € 26,241 in a study published in year 2005 [12] –
this cost factor seems low when considering that only
one single MRSA-infection not avoided by screening and
decontaminationcancausecostsofthesamemagnitude.
Inconsequence,furthercalculationswithintheframework
ofthisstudyshowedthat35nosocomialMRSA-infections
andassociatedadditionalcostsofabout€200,000could
besavedthroughscreening.Afterdeductingtheexpenses
forinitialscreenings,thisresultedinanetsavingofabout
€175,000in19months.Similarresultshavebeenfound
by Jernigan et al. [21] already in 1995 who conducted a
cost-to-benefit analysis for MRSA-screenings in a 700
beds university hospital in Virginia. As a result, MRSA-
screening led to a net saving of about $ 462,000.
Rationale for the pharmaceutical
industry
RIEMSER Arzneimittel AG, being a part of the health care
system,hasavitalandethicalinterestintheoptimization
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that it remains affordable. Nosocomial infections with
MRB cause extensive additional costs that may have a
destabilizing effect on the healthcare system and they
arethereforeinconflictwiththisinterest.Theabovedata
show, that the additional costs are primarily caused by
increased employment of the medical infrastructure and
resources such as prolonged hospitalization and more
intensive care provided by staff rather than by use of
antibiotics or diagnostic medicinal products provided by
pharmaceuticalcompanies.Asapharmaceuticalcompany
cannot profit from this it is more reasonable to support
the development of new structures for the prevention
and control of MRB and to become a relevant partner
within this structure and to develop further in this field.
The previously described results are encouraging since
they demonstrate that even relatively simple and cost
efficient measures such as an MRSA-screening can lead
toconsiderablecostsavingsandevenprotectthepatients
against severe infections.
Cooperation of the relevant
partners
Currently available knowledge about the risk factors en-
hancingtheemergenceandtransmissionofMRBclarifies
that no single health care facility can eradicate these
bacteria on its own within an isolated setting. Many risk
factors are beyond the influence of an individual facility.
The establishment of an effective prevention and control
strategyrequiresthecooperationandnetworkingbetween
all relevant actors and competencies of the health care
system.
The selection pressure caused by antibiotics for example
is a relevant risk factor for the development of multi-
resistance [22], which can be counteracted to primarily
by controlled usage of antibiotics [23]. Therefore, con-
trolledchangesoftreatmentstrategieswithinonehealth
care institution or between different health care institu-
tions(“antibioticcycling”)arenecessarytopreventmulti-
resistance.
The mutual exchange of knowledge and therapeutic ex-
perience as well as an understanding of the local resist-
ancesituationareprerequisitesforthesuccessfulestab-
lishment of such a change strategy. Another example il-
lustrating the necessity for extensive cooperation is the
fact that the duration of decontamination and recovery
ofMRSA-patientsmaybelongerthantheirhospitalization
[24], [25]. Based on this knowledge, adequate follow-up
measures within the ambulatory environment have to be
established in order to ensure successful decontamina-
tion after the patient has left the hospital – under the
reasonable assumption that MRSA patients require an
individual case management which has to begin in hos-
pital and needs to be continued after the patient has left
the hospital until all factors inhibiting full recovery are
eliminated. The spreading of relatively new epidemic
S. aureus strains causing very progressive courses of
diseases in otherwise healthy patients previously at low
risk (community onset) bears the potential hazard that
these species establish themselves as new nosocomial
pathogens [26], [27], [28]. In this context we need to ask
on the basis of which cooperation the transmission of
theseinpartextremelyaggressiveformsofbacteriafrom
outpatients into health care facilities can be stopped.
These examples, exclusively from an infective-epidemio-
logical point of view, already demonstrate the necessity
for an interdisciplinary networking for the prevention and
control of MRB.
The primary target is the establishment of an optimal
strategy for the prevention, diagnosis and treatment of
infections caused by MRB which includes all relevant
partners in the healthcare system and gives them the
opportunity to participate in the generation of additional
value. Providing an individualized and integrated therapy
under efficient utilization of the medical infrastructure is
the most important parameter for patients. Health care
institutions must be able to profit from rapid access to
therapeutic standards, an effective utilization of the re-
sources and the reduction of additional costs. Improved
cost-to-benefit relations and the chance to conduct reli-
able analyses of the cost driving factors are the key
factors for the health payers. For a pharmaceutical com-
pany, planning reliability resulting from a stable and af-
fordable healthcare system is especially important since
onlysuchasystemwillprovidetheenvironmentnecessary
for value adding innovations.
Essential for the cooperation is the sharing of knowledge
and experience for the benefit of all partners. The result-
ingtransferofknowledgewillallowacontinuousevolution
of the system and the participating partners.
The pharmaceutical company Riemser Arzneimittel AG
recognizes HIC@RE as an infrastructure project in which
this integration and networking through the participation
ofrelevantpartnersshallberealizedinordertoestablish
an integrated care of patients with a maximum of effi-
ciency in one of the strategic core competencies of the
company.
Apart from the therapy of infections caused by MRB and
theincreasinglyimportantClostridium-difficileassociated
diarrhea, the expertise of RIEMSER Arzneimittel AG also
includes the therapy of the drug-resistant tuberculosis.
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